In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer

Adi Pais, Chidambaram Gunanathan, Raanan Margalit, Inbal Eti Biton, Ady Yosepovich, David Milstein, Hadassa Degani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Histologic overexpression of the estrogen receptor a (ER) is a well-established prognostic marker in breast cancer. Noninvasive imaging techniques that could detect ER overexpression would be useful in a variety of settings where patients' biopsies are problematic to obtain. This study focused on developing, by in vivo MRI, strategies to measure the level of ER expression in an orthotopic mouse model of human breast cancer. Specifically, novel ER-targeted contrast agents based on pyridine-tetra-acetate-Gd(III) chelate (PTA-Gd) conjugated to 17β-estradiol (EPTA-Gd) or to tamoxifen (TPTA-Gd) were examined in ER-positive or ER-negative tumors. Detection of specific interactions of EPTA-Gd with ER were documented that could differentiate ER-positive and ER-negative tumors. In vivo competition experiments confirmed that the enhanced detection capability of EPTA-Gd was based specifically on ER targeting. In contrast, PTA-Gd acted as an extracellular probe that enhanced ER detection similarly in either tumor type, confirming a similar vascular perfusion efficiency in ER-positive and ER-negative tumors in the model. Finally, TPTA-Gd accumulated selectively in muscle and could not preferentially identify ER-positive tumors. Together, these results define a novel MRI probe that can permit selective noninvasive imaging of ER-positive tumors in vivo.

Original languageEnglish
Pages (from-to)7387-7397
Number of pages11
JournalCancer Research
Volume71
Issue number24
DOIs
Publication statusPublished - Dec 15 2011

Fingerprint

Estrogen Receptors
Magnetic Resonance Imaging
Breast Neoplasms
Neoplasms
Acetates
Tamoxifen
Contrast Media
Blood Vessels
Estradiol
Perfusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. / Pais, Adi; Gunanathan, Chidambaram; Margalit, Raanan; Biton, Inbal Eti; Yosepovich, Ady; Milstein, David; Degani, Hadassa.

In: Cancer Research, Vol. 71, No. 24, 15.12.2011, p. 7387-7397.

Research output: Contribution to journalArticle

Pais, Adi ; Gunanathan, Chidambaram ; Margalit, Raanan ; Biton, Inbal Eti ; Yosepovich, Ady ; Milstein, David ; Degani, Hadassa. / In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. In: Cancer Research. 2011 ; Vol. 71, No. 24. pp. 7387-7397.
@article{c395dadaf8de42f4ace69750433c64a0,
title = "In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer",
abstract = "Histologic overexpression of the estrogen receptor a (ER) is a well-established prognostic marker in breast cancer. Noninvasive imaging techniques that could detect ER overexpression would be useful in a variety of settings where patients' biopsies are problematic to obtain. This study focused on developing, by in vivo MRI, strategies to measure the level of ER expression in an orthotopic mouse model of human breast cancer. Specifically, novel ER-targeted contrast agents based on pyridine-tetra-acetate-Gd(III) chelate (PTA-Gd) conjugated to 17β-estradiol (EPTA-Gd) or to tamoxifen (TPTA-Gd) were examined in ER-positive or ER-negative tumors. Detection of specific interactions of EPTA-Gd with ER were documented that could differentiate ER-positive and ER-negative tumors. In vivo competition experiments confirmed that the enhanced detection capability of EPTA-Gd was based specifically on ER targeting. In contrast, PTA-Gd acted as an extracellular probe that enhanced ER detection similarly in either tumor type, confirming a similar vascular perfusion efficiency in ER-positive and ER-negative tumors in the model. Finally, TPTA-Gd accumulated selectively in muscle and could not preferentially identify ER-positive tumors. Together, these results define a novel MRI probe that can permit selective noninvasive imaging of ER-positive tumors in vivo.",
author = "Adi Pais and Chidambaram Gunanathan and Raanan Margalit and Biton, {Inbal Eti} and Ady Yosepovich and David Milstein and Hadassa Degani",
year = "2011",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-11-1226",
language = "English",
volume = "71",
pages = "7387--7397",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer

AU - Pais, Adi

AU - Gunanathan, Chidambaram

AU - Margalit, Raanan

AU - Biton, Inbal Eti

AU - Yosepovich, Ady

AU - Milstein, David

AU - Degani, Hadassa

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Histologic overexpression of the estrogen receptor a (ER) is a well-established prognostic marker in breast cancer. Noninvasive imaging techniques that could detect ER overexpression would be useful in a variety of settings where patients' biopsies are problematic to obtain. This study focused on developing, by in vivo MRI, strategies to measure the level of ER expression in an orthotopic mouse model of human breast cancer. Specifically, novel ER-targeted contrast agents based on pyridine-tetra-acetate-Gd(III) chelate (PTA-Gd) conjugated to 17β-estradiol (EPTA-Gd) or to tamoxifen (TPTA-Gd) were examined in ER-positive or ER-negative tumors. Detection of specific interactions of EPTA-Gd with ER were documented that could differentiate ER-positive and ER-negative tumors. In vivo competition experiments confirmed that the enhanced detection capability of EPTA-Gd was based specifically on ER targeting. In contrast, PTA-Gd acted as an extracellular probe that enhanced ER detection similarly in either tumor type, confirming a similar vascular perfusion efficiency in ER-positive and ER-negative tumors in the model. Finally, TPTA-Gd accumulated selectively in muscle and could not preferentially identify ER-positive tumors. Together, these results define a novel MRI probe that can permit selective noninvasive imaging of ER-positive tumors in vivo.

AB - Histologic overexpression of the estrogen receptor a (ER) is a well-established prognostic marker in breast cancer. Noninvasive imaging techniques that could detect ER overexpression would be useful in a variety of settings where patients' biopsies are problematic to obtain. This study focused on developing, by in vivo MRI, strategies to measure the level of ER expression in an orthotopic mouse model of human breast cancer. Specifically, novel ER-targeted contrast agents based on pyridine-tetra-acetate-Gd(III) chelate (PTA-Gd) conjugated to 17β-estradiol (EPTA-Gd) or to tamoxifen (TPTA-Gd) were examined in ER-positive or ER-negative tumors. Detection of specific interactions of EPTA-Gd with ER were documented that could differentiate ER-positive and ER-negative tumors. In vivo competition experiments confirmed that the enhanced detection capability of EPTA-Gd was based specifically on ER targeting. In contrast, PTA-Gd acted as an extracellular probe that enhanced ER detection similarly in either tumor type, confirming a similar vascular perfusion efficiency in ER-positive and ER-negative tumors in the model. Finally, TPTA-Gd accumulated selectively in muscle and could not preferentially identify ER-positive tumors. Together, these results define a novel MRI probe that can permit selective noninvasive imaging of ER-positive tumors in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84255199622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255199622&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-1226

DO - 10.1158/0008-5472.CAN-11-1226

M3 - Article

C2 - 22042793

AN - SCOPUS:84255199622

VL - 71

SP - 7387

EP - 7397

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -